Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ValiRx has entered into an agreement with Imperial College and Oxford University to advance the development of VAL101 and VAL 201, the company's lead therapeutics.
Subscribe to our email newsletter
Under the agreement, Imperial College will take up the responsibility for VAL101’s late preclinical development.
The aim is to provide validation for the GeneICE clinical applications and validation for the use of GeneICE technology as a silencing tool
However, Oxford University is expected to carry out the late preclinical development of VAL201 to combat hormone refractory prostate cancer and also further indications of hormone induced unregulated growth.
All intellectual and commercial property rights from the work undertaken by both Oxford University and Imperial College will continue to be owned by ValiRx.
ValiRx CEO Satu Vainikka said they look forward to ValiRx benefiting greatly from this association and for the future successful progress and development of therapeutic medicines.